Browsing Centro Académico de Salud (CAS) by Subject "Hepatocellular carcinoma"
Now showing items 1-8 of 8
-
Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina
(Baishideng Publishing Group Inc, 2018-01-27)Abstract Aim: To investigate any changing trends in the etiologies of hepatocellular carcinoma (HCC) in Argentina during the last years. Methods: A longitudinal cohort study was conducted by 14 regional hospitals ... -
Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina.
(Baishideng Publishing Group, 2018-01-27)AIM: To investigate any changing trends in the etiologies of hepatocellular carcinoma (HCC) in Argentina during the last years. METHODS: A longitudinal cohort study was conducted by 14 regional hospitals starting in ... -
Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
(Wolters Kluwer Health, Inc., 2016-04-28)BACKGROUND AND AIM: The Up-to-7 criteria on the basis of the explanted liver features categorize patients at higher risk of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). The aim of this study ... -
LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study
(Elsevier, 2020-11)Abstract Introduction and objectives: The liver imaging reporting data system (LI-RADS) for hepatocellular carcinoma (HCC) was proposed to standardize and enhance consensus of reporting. However, clinical utility of LI-RADS ... -
Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort
(Wiley, 2021-04)Abstract Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been ... -
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study
(Wiley, 2021-12)Abstract Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared with best ... -
SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism
(Wiley, 2021-07)Abstract Background and aims: Non-alcoholic fatty liver (NAFLD) and its more serious form non-alcoholic steatohepatitis increase risk of hepatocellular carcinoma (HCC). Lipid metabolic alterations and its role in HCC ... -
Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
(Baishideng Publishing Group, 2021-06)Abstract Although hepatocellular carcinoma is considered a highly lethal malignancy, recent therapeutic advances have been achieved during the last 10 years. This scenario resulted in an unprecedented improvement in ...